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Abstract Cumulative risk assessment (CRA) is of
major importance and one of the biggest challen-
ges for the future as a legal requirement within the
EU for active substances used in plant protection
products (PPP) and biocidal products (BP). Therefo-
re, it is important to develop a methodology to
take into account cumulative and synergistic effects
for both active substances and substances of
concern (SoC). The implementation of cumulative
aspects in regulatory decisions is highly demanded
and promoted by EU parliament, EU commission,
European Food Safety Authority (EFSA), European
Chemicals Agency (ECHA) and national authorities.
Based on EFSA’s and ECHA’s work on CRA, the
Federal Institute for Risk Assessment (BfR) drafted a
concept on how to take cumulative aspects into
account in the regulatory context in risk assess-
ments for operators, consumers and other
uninvolved third parties. Application of this con-
cept as part of the routine risk assessment for PPP
and BP is envisaged as soon as suitable experience
has been gained in a testing phase. The BfR draft
concept uses dose-addition of individual active
substances and SoC as the toxicological standard
concept for CRA and proposes a tiered approach. It
recommends to start with calculation of a hazard
index (HI) for all relevant substances contained in
the PPP or BP under consideration. Proceeding to
higher tiers is currently foreseen if the HI is larger
than 1, i.e., an unacceptable risk cannot be exclu-
ded. In higher tiers, the HI should be calculated
with respect to common targets and might consi-
der effect-specific NOAEL’s (No Observed Adverse
Effect Level) or relative potency factors, if available.
Refinements should consider both the toxicity and
the exposure part of the CRA and will depend on
availability of relevant data. BfR acknowledges the
complexity of the refinement work in mixture risk
assessment to be done. The exposure assessment for
operators, bystanders/residents and workers as well
as the acute exposure assessment for consumers
rely mainly on the active substances in a PPP or BP
under consideration or on combinations of pro-
ducts for which simultaneous use is notified.
Chronic consumer exposure assessment needs to
take into account all relevant substances contained
in the PPP or BP under consideration, but also the
residue background of other pesticides in food,
which have to be derived from representative food
monitoring programmes. A representative food
monitoring database is currently being developed.
The assessment requires the application of complex
probabilistic methods. It is planned that BfR will
review the chronic CRA for each active substance
and each CAG regularly as soon as all essential
monitoring data are available. It is planned to carry
out case studies on the impact on regulatory
decisions. The paper is intended to promote further
discussions of risk assessors, risk managers as well
as stakeholders in this area on the applicability of
CRA in routine authorisation procedures for PPP
and BP and to encourage the flexible use of stra-
tegies in CRA.
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1 Introduction
According to article 14 of Regulation (EC) No.
396/2005 regarding decisions on applications con-
cerning maximum residue levels (MRL), ‘‘known
cumulative and synergistic effects shall be taken
account of, when the methods to assess such effects
are available.’’
According to Regulation (EC) 1107/2009 a plant
protection product (PPP) shall meet the following
requirements: ‘‘It shall have no immediate or delayed
harmful effect on human health, including that of
vulnerable groups, or animal health, directly or
through drinking water (taking into account sub-
stances resulting from water treatment), food, feed or
air, or consequences in the workplace or through
other indirect effects, taking into account known
cumulative and synergistic effects where the scienti-
fic methods accepted by the Authority to assess such
effects are available.’’
For biocidal products (BP), article 8 to Regulation
(EU) No. 528/2012 states: ‘‘Where the evaluating
competent authority considers that there are con-
cerns for human health, animal health or the
environment as a result of the cumulative effects
from the use of biocidal products containing the
same or different active substances, it shall document
its concerns (…) and include this as part of its
conclusions.’’
As a consequence, cumulative and synergistic
effects between different active substances as well as
substances of concern (SoC; e.g. synergists, safeners,
co-formulants of concern) have to be considered in
all regulatory decisions concerning PPP and BP if
scientifically robust methods are available to identify
and assess them. Thus, there is the legal requirement
to account for cumulative effects before active sub-
stances can be approved for use in PPP and BP, in
MRL setting and during authorisation of PPP and BP
on zonal and national level. Furthermore, human
health assessment of cumulative effects is an im-
portant criterion in the assessment of samples in food
monitoring.
In general, the same guidance and principles as
laid down in the data requirements for PPP in
accordance with Regulation (EC) No. 1107/2009 and
for biocides in Regulation No. 528/2012 or any rele-
vant guidance document for conventional exposure
and risk assessment apply also to cumulative expos-
ure and risk assessment.
The implementation of cumulative aspects in the
risk assessment for operators, consumers and other
uninvolved third parties in the regulatory context is
highly demanded and promoted by EU Parliament,
EU Commission, EFSA and national authorities. Alt-
hough insufficiently supported by the current legal
data requirements, the complexity of these assess-
ments has to be accounted for by the development of
refined methods for exposure assessment, improved
toxicological concepts and methodological support
including IT tools and alternatives for conventional
methods to avoid further animal testing.
Since 2008, EFSA published several opinions on
issues of cumulative consumer risk assessment
(EFSA 2008, 2009, 2012, 2013a, b). Guidance on risk
assessment from combined exposure to multiple
biocidal substances within a single biocidal pro-
duct was recently published by ECHA (2013). It
follows the tiering principles of refinement as
described in Fig. 1 within the WHO/IPCS Frame-
work on Combined Exposure (Meek et al. 2011).
This ECHA guidance is based on different recent
documents of the Scientific Committee on Health
and Environmental Risks (SCHER), the Scientific
Committee on Consumer Safety (SCCS), the Scien-
tific Committee on Emerging and Newly Identified
Health Risks (SCHER, SCCS, SCENIHR 2011) and
some publications found through a literature review.
Based on this preceding work, BfR drafted a con-
cept on how to take cumulative aspects into account
in the risk assessments for operators, consumers and
other uninvolved third parties in the context of PPP
and BP regulation.
Additionally, BfR is currently working on research
projects in the field of CRA for operators, consumers
and other uninvolved third parties. For environ-
mental risk assessment, drafts for technical guidance
documents and methods to assess cumulative effects
and multiple residues were already developed by the
Federal Environmental Agency (UBA).
Based on the EFSA and ECHA guidance, the risk
assessment from combined exposure to one or mul-
tiple chemicals can be classified into the following
three situations:
1. combined exposure to multiple substances by one
source
of release(s) and/or use(s).
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2. combined exposure to multiple substances by
different sources
of release(s) and/or use(s).
3. aggregated exposure to single substances from
different sources
of release(s) and/or use(s).
Irrespective of the situation, the assessment should
be based on:
• the scientific state-of-the-art;
• simple concepts to allow routine application;
• tiered approaches starting with simple, conserva-
tive and deterministic exposure assumptions and,
if required, continuing with refinements, e.g. by
probabilistic methods if available;
• harmonised concepts which are used throughout
all involved agencies/parties.
As a starting point, this paper deals with human
health risk assessment from combined exposure only,
while questions of aggregate exposure assessment
are not covered herein. Furthermore, possible com-
bination effects between PPP and BP on the one hand
and substances falling under the scope of further
regulations (pharmaceuticals, veterinary pharma-
ceuticals, food additives, contaminants) on the other
Fig. 1 Simplified overview of
the assessment method: The
diagram shows the risk
assessed for each population
type: primary and secondary
exposure (ECHA 2013)
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hand have been largely disregarded in previous
concepts and will also not be covered by this BfR
concept.
Employing CRA in regulatory procedures, especi-
ally when higher tier probabilistic calculations get
involved, requires not only efforts by risk assessors,
but also by risk managers in terms of transparent
communication of the results of such assessments. To
be able to base regulatory decisions on CRA, risk
managers have to clearly define which protection
goal is aimed for operators, consumers and other
uninvolved third parties. It has to be clarified and
communicated to the public which results indicate
acceptability of the risk and which do not.
It is essential to develop concepts that do not lead
to further data requirements concerning animal
studies and that support the necessary paradigm
shift in risk assessment strategies while taking on
board all stakeholders including the applicants.
2 Toxicological assessment of mixtures
Humans are exposed to different chemical substan-
ces which may act independently or interact. For
assessing combined effects of chemical mixtures,
several approaches have been developed in recent
years by different bodies, which are also applicable to
human health risk assessment of PPP and BP. In the
case that chemicals act independently but have a
similar mode of action, dose-addition may be assu-
med, while for dissimilar mode of action effect-
addition is considered. If interaction has to be ex-
pected, antagonism (lower effect than expected for
dose addition) or synergism (higher effect than ex-
pected for dose addition) might occur.
In accordance with conclusions from the discussi-
ons on EU level (Kortenkamp et al. 2009) BfR
proposes to use dose-addition as the standard con-
cept for CRA in the first tier of a tiered approach. This
concept is predictive and sufficiently conservative for
chemicals with similar and dissimilar mode of action.
Since information on the mode of action of active
substances or SoC used in PPP or BP is often limited,
cumulative assessments can not be refined by grou-
ping for similar modes of action in these cases.
The assessment of possible cumulative effects of
active substances in PPP and BP normally relies on
the available toxicological studies with a single sub-
stance. Data requirements for active substances
comprise an extensive set of toxicological studies
(in vitro and in vivo), which normally meet the cri-
teria of good laboratory praxis (GLP) and are
conducted in accordance with internationally ac-
cepted test protocols (e.g. OECD test guidelines).
Usually several dose levels are tested which are al-
ways clearly above the expected human exposure
level. The principal aim of these studies is—besides
recognition of critical effects—the identification of
the respective NOAEL. From the most appropriate
studies for the most sensitive animal species the re-
spective toxicological reference values are derived,
e.g. the Acceptable Daily Intake (ADI) covering oral
long-term exposure, the A[O]EL (Acceptable [Opera-
tor] Exposure Level) for the operator, worker,
bystander and resident safety and, where necessary,
the Acute Reference Dose (ARfD) covering oral short-
term exposure.
For assessing SoC in PPP and BP, normally only
safety data sheets are available but no toxicological
studies as for active substances. To fill this gap, first
drafts of alternative concepts have been developed
and are currently under discussion. Existing refe-
rence values from other areas of regulation, such as
the occupational exposure limit value (MAK, MAC) or
the Derived No Effect Level (DNEL) are applicable
only to a limited extent because the information on
which these reference values are based is not always
assessable, the assessment was not performed by in-
dependent bodies or peer reviewed or is based on
human data.
Cumulative assessments assuming dose-addition
are normally based on the toxicological data for the
single substances and appropriate calculation mo-
dels. The BfR concept is making use of the following,
internationally acknowledged standards:
• Hazard quotient, HQ (ratio of exposure and
toxicological reference value derived for each
single substance in the product/mixture).
• Hazard index, HI [without and with consideration
of ‘‘Cumulative Assessment Groups’’ (CAG)]
• Reference point index, RI (consideration of target
or effect specific NOAEL’s).
• Relative potency factors (RPF).
The calculations use internationally agreed toxi-
cological reference values or benchmark dose/NOAEL
values mainly from animal studies and compare
them to exposure estimates (see Sects. 3 and 4 for
further details on exposure). The resulting exposure/
toxicity ratios (HQs) for all active substances in the
mixture and those SoC for which a reference value
can be derived are then added. If the sum (i.e. HI) is
below or equal to 1, the cumulative risk is deemed
being acceptable. However, it should be noted that
this approach is only justified if dose-addition or
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effect-addition applies. Especially, possible synergistic
effects cannot be appropriately covered.
If the sum of the ratios is higher than 1 indicating
the possibility of an unacceptable risk with respect to
human health, a refined assessment is necessary. This
may be achieved by restricting it to those compounds
included in one CAG, because these compounds are
much more likely to exhibit similar effects. CAGs may
be based on common chemical structures, common
target organs, common toxicological effects or com-
mon mechanisms of action. The definition of CAGs is
currently ongoing on European level and is urgently
needed for adequate and harmonized CRA for PPP
and BP. In 2013, EFSA published a Scientific Opinion
on the identification of pesticides to be included in
cumulative assessment groups and proposed CAGs
for the thyroid and nervous system, i.e. CAGs based
on common target organs (EFSA 2013a). Agreement
on further CAGs (e.g. liver, reproductive system) is
expected in 2015.
US EPA already defined CAGs for organophos-
phates, N-methyl carbamates, pyrethroids, 1,3,5-
triazines and chloroacetanilides based on same
mechanism of action and common chemical struc-
tures (available at http://www.epa.gov/oppsrrd1/
cumulative).
Having in mind that refinements should not be
restricted to either the toxicity or the exposure part
of the CRA, but should in the first place be applied to
that part which is easier to refine (depending on
availability of data and the complexity of the refi-
nement work to be done), BfR proposes the following
tiered approach of assessments starting with cumu-
lative assessment in Tier II in accordance with the
scheme proposed by ECHA (2013) which is displayed
in Fig. 1:
• Tier I HQ for each substance under consideration
(no combined risk assessment).
• Tier II HI for all substances under consideration
(without taking into account CAGs or mode/me-
chanism of action).
• Tier IIIA HI(to) for all substances under considera-
tion with a common target organ/system (i.e.
attributed to the same CAG or the same sub-group
of a CAG, if appropriate).
• Tier IIIB aHI(to) (‘‘adjusted Hazard Index’’) for all
substances under consideration with a common
target organ/system, calculated by utilisation of
target-specific reference doses (NOAEL’s and safety
factor(s)).
• Tier IIIC aHIðtoÞ for all substances under consi-
deration with a common target organ/system
and a common mode of action, calculated by
taking into account the relative potency of
substances.
For the time being, BfR decided not to develop
specific models based on effect-addition and to base
its concept for CRA on dose-addition only. At this
stage, only Tier II evaluations can be used in regula-
tory procedures while refinements in Tier III can only
be applied to a limited extent because only few CAGs
are currently available. Regarding Tier IIIC, a stan-
dardized methodology to derive relative potency
factors for a CAG has to be developed.
3 Cumulative risk assessment with respect
to application safety
3.1 General considerations
CRA considers different substances during the same
exposure period. All active substances and SoC ope-
rators and other unintentionally involved people may
be simultaneously exposed to, have to be taken into
consideration for PPP and BP. SoC means any sub-
stance which has an inherent capacity to cause an
adverse effect on humans and is present or is pro-
duced in a product in sufficient concentration that
the occurrence of such an effect is likely. SoC are
identified according to the corresponding regulati-
ons and guidance documents for BP and PPP. For the
time being, CRA is restricted to individual products
or intended mixtures of products. Established ex-
posure models will be used for the exposure
assessment.
3.2 Consideration of cumulative risk assessment
in the context of PPP and BP authorisation
The CRA based on the HI and further consideration of
CAGs follows a tiered approach. Appropriate refe-
rence values must be available for each tier. In Tier II
deterministic point estimates and worst-case
assumptions might be included. However, if this re-
sults in exposure estimates exceeding the reference
value, further refinement using more realistic toxi-
cological data or exposure patterns is required.
Further risk mitigation measures can be considered
as well. If the cumulative exposure results in a non-
acceptable risk, a corresponding exposure study with
the product may overrule this assessment. In general,
a HI below or equal to 1 (default reference HI) is
acceptable. However, if synergistic effects are
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expected, this value should be adapted on a case-by-
case basis.
• Tier I HQ for each relevant substance contained in
the PPP or BP under consideration (single sub-
stance basis, no CRA).
Tier I comprises the evaluation of each substance
alone. The HQ of each relevant substance has to
be B1. If a non-acceptable risk (i.e. HQ [1) is
identified for at least one substance even under
consideration of all possible risk mitigation mea-
sures or exposure refinements, the assessment is
terminated.
• Tier II HI for all relevant substances contained in
the PPP or BP under consideration (without taking
into account CAGs).
The HI is calculated by summing up the HQs of all
relevant components. If the HI is B1, the risk is
acceptable; if the HI is[1, proceeding to Tier III is
required. Alternatively, further risk mitigation
measures or a refinement of the exposure assess-
ment might be possible.
• Tier IIIA HI(to) for all those relevant substances
contained in the PPP or BP under consideration
with a common target organ/system (i.e. attribu-
ted to the same CAG).
The HI(to) is calculated by combining HQs for all
substances with a common target organ or system
without the use of target-specific reference values.
If the HI(to) is B1, the risk is acceptable. If the HI(to)
is [1, refinement according to Tier IIIB or IIIC
might be possible. Alternatively, further risk mi-
tigation measures or a refinement of the exposure
assessment might be possible.
• Tier IIIB aHI(to), i.e. adjusted HI for all those
relevant substances contained in the PPP or BP
under consideration with a common target or-
gan/system (attributed to the same CAG),
calculated by utilisation of target-specific refe-
rence values.
The aHI(to) is calculated by combining target-
specific reference values if a non-acceptable risk
has been identified in Tier IIIA. If the aHI(to) is B1,
the risk is acceptable. If not, further risk mitiga-
tion measures or a refinement of the exposure
assessment might be possible.
• Tier IIIC aHIðtoÞ, i.e. adjusted HI for all those
relevant substances contained in the PPP or BP
under consideration with a common target
organ/system and a common mode of action,
calculated by taking into account the relative
potency of substances (relative potency
factors).
4 Cumulative risk assessment with respect
to residues in food
4.1 General considerations
Consumers are normally exposed to a complex pat-
tern of multiple residues with low individual levels
which are consumed in a broad range of food items.
Several methods are available for cumulative ex-
posure assessment in food. They differ by their
degree of complexity. Methods used range from
simple deterministic calculation models (e.g. EFSA
2013b) to laborious probabilistic models (e.g. EFSA
2009, 2012).
Concerning the toxicological assessment of cu-
mulative residues, a tiered approach is proposed
which is detailed in Sect. 4.2.
4.2 Consideration of cumulative risk assessment
in the context of PPP and BP authorisation
4.2.1 Acute cumulative risk assessment related
to the GAP(s) under consideration
As far as acute (short-term) exposure is concerned, it
is justified to focus the cumulative exposure assess-
ment on those substances which are contained in the
PPP or BP under consideration, since consumers are
likely to get exposed to residues of these substances
simultaneously via treated food. Exposure to further
active substances resulting from other applications or
from differently treated other food items, which are
all consumed within a short time period (i.e. within
24 h) are not taken into account.
• Tier I HQ for each relevant substance contained in
the PPP or BP under consideration and for which
an ARfD has been allocated (single substance
basis; no CRA).
For all active substances and/or safeners in a
PPP, which are acutely toxic, the HQ is calcula-
ted. This is done for each substance by
performing a deterministic IESTI calculation
[international estimated short-term intake
(IESTI); point estimate] with the calculation
models EFSA PRIMo [Pesticide Residue Intake
Model (PRIMo), EFSA 2008] and NVS II (German
consumption model, BfR 2011) and based on the
respective ARfD of the substance. If a non-
acceptable risk is identified for at least one
substance, the assessment is terminated.
• Tier II HI for all relevant substances contained in
the PPP or BP under consideration and for which
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an ARfD has been allocated (without taking into
account CAGs).
Summing up the HQs obtained in Tier I results in
the HI as already described in Sect. 3.2 for opera-
tors, workers, bystanders and residents.
If Tier II results in a HI[1, the assessment needs to
be refined. This is done in Tier IIIA by restricting
the cumulative assessment to those active sub-
stances which belong to the same CAG because
they act on a common target organ/system.
• Tier IIIA HI(to) for all those relevant substances
contained in the PPP or BP under consideration,
for which an ARfD has been allocated and which
act on a common target organ/system (i.e. attri-
buted to the same CAG).
If Tier IIIA still results in a HI(to) [1, Tier IIIB
provides the possibility to derive ARfDs for speci-
fic target organs and select the appropriate ARfD
which is then used to calculate the so called
aHI(to).
• Tier IIIB aHI(to), i.e. adjusted HI for all those
relevant substances contained in the PPP or BP
under consideration, for which an ARfD has been
allocated and which act on a common target
organ/system (attributed to the same CAG), calcu-
lated by utilisation of target-specific reference
values.
• Tier IIIC aHIðtoÞ, i.e. adjusted HI for all those
relevant substances contained in the PPP or BP
under consideration, for which an ARfD has been
allocated and which act on a common target
organ/system with a common mode of action,
calculated by taking into account the relative
potency of substances (relative potency factors).
If Tier IIIC finally results in a aHI(to*) [1, a health
risk for consumers cannot be excluded and
authorization of the use(s) under evaluation is
rejected.
Only the specific contribution of the PPP or BP
under evaluation to the overall short-term intake is
considered, though consumers might get exposed to
further residues of the same active substances or to
residues of other active substances from the same
CAG with their food during the time period relevant
for short-term assessment (normally 24 h). However,
from typical detection frequencies and residue levels
in monitoring programmes it is obvious that a worst
case exposure as high as that one considered in the
assessment (based on large portion, highest residue
from supervised trials reflecting the most critical
GAP, variability factor etc.) is extremely unlikely to
occur for more than one substance at a time.
Restricting the acute cumulative assessment to resi-
dues from the use(s) under consideration therefore
seems to be sufficiently conservative. The efforts
needed to achieve more realistic exposure calculati-
ons by applying laborious, non-routine probabilistic
models are not counterbalanced by the additional
gain of information.
4.2.2 Chronic cumulative risk assessment
The use of the PPP or BP under consideration nor-
mally provides only a minor contribution to the
overall chronic exposure of consumers to residues of
the respective active substances and of substances
belonging to the concerned CAGs. Summing up ha-
zard quotients (on basis of the individual ADI values)
for the active substances contained in the PPP or BP
as for the acute cumulative assessment is therefore
not recommended.
The calculation parameters currently used in
chronic risk assessment for a single substance reflect
a very conservative scenario: it is assumed that all
food items contain residues of the active substance,
though this is nearly never observed in practice. For
those food commodities which are derived from the
uses under consideration, median residue levels
(STMR/STMR-P) obtained in supervised field trials are
used, while for all other food commodities residues at
MRL level are assumed. The exposure is then com-
pared to the ADI value. If required, further
refinement is possible by replacing MRLs by further
STMR/STMR-P values, which are obtained from the
residue trials underlying the MRLs.
Having the conservative calculation scenario for
each single active substance in mind, the chronic
consumer risk assessment in the framework of PPP or
BP authorization is considered as being sufficiently
conservative and covering also possible cumulative
effects.
In principle, a more realistic assessment of the
overall chronic exposure of consumers to residues of
a specific pesticide or pesticides of a specific CAG
requires the use of statistical programmes which are
able to handle distributions of monitoring and con-
sumption data (e.g. Monte Carlo simulation).
Representative monitoring data are needed to cal-
culate realistic background concentrations. On
European level, the monitoring database is currently
under development. The EU multi-annual control
programme according to Art. 29 of Reg. (EC) No.
396/2005 (monitoring) is running already for a cou-
ple of years now and the largest part of the envisaged
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food basket has already been covered. However,
preparation of data for the use in distribution-based
calculation programmes is still ongoing.
One important issue in deriving realistic back-
ground concentrations is the handling of ‘‘non-
detects’’ (ND), i.e. of the (usually large) number of
monitoring samples, in which residues of the re-
spective pesticide were below the limit of
quantification (LOQ). Among others, the following
options (or combinations thereof) are currently
discussed:
– Use the number of the LOQ for a ND sample.
– Use the number of  LOQ for a ND sample.
– Treat ND samples as being zero.
The last option (i.e., to treat ND samples as being
zero) could only be used for those commodities
which are known to have never been treated with the
pesticide in question. However, the worldwide app-
lication pattern of pesticides is normally not known.
As the European programme, the German food
monitoring relies on a representative food basket.
The German representative food basket has been
composed on the basis of national consumption
surveys. The national multi-annual monitoring pro-
gramme is intended to cover the food basket once
within 6 years. Sampling frequencies differ between
foods. The first monitoring cycle (after having re-
structured the German monitoring to cover needs of
consumer risk assessment) will be complete in 2014.
As soon as all these data are available, BfR intends to
calculate the background concentration for German
consumers. As already mentioned above, the ques-
tion of how to consider non-detects is of key
importance for the results.
In principle, chronic CRA in the framework of an
authorisation procedure of a PPP could be conducted
as follows: for all uses under consideration (i.e., for all
pesticide/commodity combinations under considera-
tion) the respective STMR value is used, while for all
other commodities and all other pesticides belonging
to the CAG under consideration the background level
is used. The calculation would be done with a dis-
tribution-based programme (e.g. Monte Carlo
simulation). However, having in mind that Monte
Carlo simulations require huge amounts of data and
time, efforts and gain in knowledge should be ba-
lanced. Especially the evaluation of minor uses not
considerably contributing to the overall food intake
might not need a full cumulative assessment, at least
not if a large number of more important uses are
already authorised for the same active substance or
other substances belonging to the respective CAG.
As already mentioned above, chronic CRA is not
expected to reveal risks which have been overlooked
in the past and is expected to be dispensable in the
context of a PPP or BP evaluation. Based on current
knowledge BfR thinks it is justified to review the
chronic CRA for each active substance and each CAG
regularly after a 6 years monitoring cycle has been
completed, but not in the context of each PPP or BP
evaluation. To check the validity of this assumption,
BfR will conduct some case studies as soon as all re-
quired monitoring data from the German (and later
on also from the EU) monitoring programmes are
available.
4.3 Consideration of cumulative risk assessment
in the context of evaluating monitoring data
4.3.1 Deriving background levels for consumer
exposure
One of the intentions of the German food monitoring
programme is to derive realistic levels of pesticide
residues to which German consumers are exposed. As
described above, the German food monitoring is ba-
sed on a representative food basket, which is covered
once every 6 years, with the first monitoring cycle
being complete in 2014 and providing for the first
time all data needed to calculate realistic back-
ground concentrations for consumers. Biocidal active
substances are not yet part of this monitoring. Such
background levels are fed into distribution-based
calculation programmes to assess the chronic cu-
mulative exposure of consumers. The results are
strongly influenced by the still pending decision on
how to include non-detects in the calculation (see
above). The largest influence is expected for pestici-
des with only few authorized uses on the one hand
and a low ADI on the other hand.
BfR intends to derive background concentrations
for each active substance and each CAG which is
available at that time, when data from the first mo-
nitoring cycle are complete.
4.3.2 Assessment of individual samples
Since residues found in individual food samples are
not assumed to be generally present at these levels in
consumed foods, only an acute risk assessment is
conducted.
• Tier I HQ for each substance which is detected in
the sample at levels CLOQ and for which an ARfD
has been allocated (single substance basis; no CRA).
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For all acutely toxic substances found in the sample
the HQ is calculated. This is done for each substan-
ce by performing a deterministic IESTI calculation
with the calculation models EFSA PRIMo and NVS II
and based on the respective ARfD of the substance.
If a non-acceptable risk is identified for at least one
substance in the sample, the assessment is
terminated.
• Tier II HI for all substances which are detected in
the sample at levels CLOQ and for which an ARfD
has been allocated (without taking into account
CAGs).
Summing up the HQs results in the HI as already
described in Sects. 3.2 and 4.1.
If Tier II results in a HI[1, the assessment needs to
be refined. This is done in Tier IIIA by restricting
the cumulative assessment to only those active
substances in the sample, which can be attributed
to the same CAG because they act on a common
target organ/system.
• Tier IIIA HI(to) for all those substances which are
detected in the sample at levels CLOQ, for which
an ARfD has been allocated and which act on a
common target organ/system (i.e., attributed to
the same CAG).
If Tier IIIA still results in a HI(to) [1, Tier IIIB
provides the possibility to derive specific ARfDs
for specific target organs and select the appro-
priate ARfD which is then used to calculate the
aHI(to).
• Tier IIIB aHI(to), i.e. adjusted HI for all those
substances which are detected in the sample at
levels CLOQ, for which an ARfD has been alloca-
ted and which act on a common target
organ/system (i.e. attributed to the same CAG),
calculated by utilisation of target-specific refe-
rence values.
• Tier IIIC aHIðtoÞ, i.e. adjusted HI for all those
substances which are detected in the sample at
levels CLOQ, for which an ARfD has been alloca-
ted and which act on a common target
organ/system with a common mode of action,
calculated by taking into account the relative
potency of substances (relative potency factors).
If Tier IIIC finally results in a aHIðtoÞ [1, a health
risk for consumers cannot be excluded.
4.4 Consideration of cumulative risk assessment
in the context of MRL setting
It is proposed that the Evaluating Member State (EMS)
for an MRL according to articles 10–12 of Regulation
(EC) No. 396/2005 continues to deliver MRL proposals
only for the commodity/pesticide combination(s) in
question without consideration of CAGs and back-
ground levels. EFSA should then in a second step
additionally consider background levels for European
consumer groups for the respective CAGs and on this
basis re-evaluate the safety of all MRLs proposed. The
proposed role of EFSA in this process results from the
fact that EFSA would collect and evaluate European
monitoring data submitted in the framework of the
EU multi-annual control programmes. Moreover,
EFSA has an overview of the consumption data re-
ported by EU MS and—in the context of Art. 12
evaluations—collects data on all GAPs authorized in
EU MS and on further aspects of the assessment (such
as processing factors or conversion factors).
If MS and EFSA would agree to the proposed two-
step procedure, no changes would result for the EMS
assessments.
5 Concluding remarks
New approaches to safety testing, including CRA, re-
quire new strategies to stringent but flexible
evaluation of the suitability and performance of me-
thods (Leist et al. 2014). The paper is intended to
promote further discussions of risk assessors, risk ma-
nagers as well as stakeholders in this area on the
applicability of CRA in routine authorisation proce-
dures for PPP and BP and to encourage the flexible use
of strategies in CRA.
Against this background, the authorities respon-
sible for the risk assessment for humans and the
environment and for the risk management of PPP in
Germany, namely the Federal Office of Consumer
Protection and Food Safety (BVL), the BfR and the
UBA, developed a German Guidance on CRA in or-
der to provide (1) the current scientific
understanding of the regulatory requirements, (2)
the available options for implementation as well as
(3) guidance on the current practice in CRA in
Germany. An overview of the German Guidance is
given in ‘‘Assessment of the risks resulting from ex-
posure to pesticide mixtures and multiple pesticide
residues to humans and wildlife’’ (Solecki et al. 2014).
It is intended to inform interested experts from in-
dustry, academia, regulatory bodies and NGOs about
the current status of the implementation of mixture
risk assessment from the perspectives of human
health risk assessment, environmental risk assess-
ment and risk management, which are interrelated
elements for the implementation of cumulative
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aspects in regulatory decisions in Germany. The
present publication is the human health part of the
German Guidance. The part related to environmen-
tal risk assessment is published elsewhere (Frische
et al. 2014).
Open Access This article is distributed under the terms of the
Creative Commons Attribution License which permits any use,
distribution, and reproduction in any medium, provided the
original author(s) and the source are credited.
References
BfR (2011) German consumption model NVS II. http://www.bfr.
bund.de/cm/349/bfr-model-for-pesticide-residue-intake-
calculations-nvs2.zip. Accessed 26 Aug 2014
ECHA (2013) Guidance for human health risk assessment vol III,
part B, chapter 4.4. http://www.echa.europa.eu/documents/
10162/15623299/biocides_guidance_human_health_ra_iii_
partb_en.pdf. Accessed 26 Aug 2014
EFSA (2008) Opinion of the scientific panel on plant protection
products and their residues to evaluate the suitability of
existing methodologies and, if appropriate, the identifi-
cation of new approaches to assess cumulative and
synergistic risks from pesticides to human health with a
view to set MRLs for those pesticides in the frame of
regulation (EC) 396/2005. EFSA J 704:1–84
EFSA (2009) Scientific opinion on risk assessment for a selected
group of pesticides from the triazole group to test possible
methodologies to assess cumulative effects from exposure
through food from these pesticides on human health.
EFSA J 7(9):1167
EFSA (2012) Guidance on the use of probabilistic methodology
for modelling dietary exposure to pesticide residues. EFSA
J 10(10):2839
EFSA (2013a) Scientific opinion on the identification of pesti-
cides to be included in cumulative assessment groups on
the basis of their toxicological profile. EFSA J 11(7):3293
EFSA (2013b) The 2010 European Union report on pesticide
residues in food. EFSA J 11(3):3130
Frische T, Matezki S, Wogram J (2014) Environmental risk
assessment of pesticide mixtures under regulation
1107/2009/EC: a regulatory review by the German Federal
Environment Agency (UBA). J Verbrauch Lebensm 9(4).
doi:10.1007/s00003-014-0916-6
Kortenkamp A, Backhaus T, Faust M (2009) State of the art
report on mixture toxicity—report, executive summary, 22
December 2009
Leist M, Hasiwa N, Rovida C, Daneshian M, Basketter D, Kimber
I, Clewell H, Gocht T, Goldberg A, Busquet F, Rossi AM,
Schwarz M, Stephens M, Taalman R, Knudsen TB, McKim J,
Harris G, Pamies D, Hartung T (2014) t-Workshop report;
consensus report on the future of animal-free systemic
toxicity testing. ALTEX 31(3):341–356. doi:10.14573/altex.
1406091
Meek ME, Boobis A, Crofton MK, Heinemeyer G, Van Raaij M,
Vickers C (2011) Risk assessment of combined exposure to
multiple chemicals: a WHO/IPCS framework. Regul Toxicol
Pharmacol 60:S1–S14
SCHER, SCCS, SCENIHR (2012) Opinion on the toxicity and
assessment of chemical mixtures, European Union. doi:10.
2772/21444
Solecki R, Stein B, Frische T, Matezki S, Wogram J, Streloke M
(2014) Paradigm shift in the risk assessment of cumulative
effects of pesticide mixtures and multiple residues to
humans and wildlife: German proposal for a new ap-
proach. J Verbrauch Lebensm 9(4). doi:10.1007/s00003-014-
0914-8
376 B. Stein et al.
123
